Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 7:48 PM
Ignite Modification Date:
2025-12-25 @ 5:24 PM
NCT ID:
NCT04659603
Pre Assignment Details:
Total 50 participants enrolled to receive tusamitamab ravtansine as single agent treatment (Cohorts A, B) or in combination with gemcitabine (Cohort C). All participants received the same dose in the respective Cohorts. The study was terminated due to the discontinuation of the overall development program of tusamitamab ravtansine by the Sponsor.
Recruitment Details:
The study was conducted at 31 centers in 10 countries. A total of 55 participants were screened from 29 March 2021 to 27 November 2023, of which 5 were screen failures. Screen failures were mainly due to not meeting the eligibility criteria.
Study:
NCT04659603
Study Brief:
Results Section:
NCT04659603